When Larry Zeitlin received a text message from an unknown number asking about an experimental drug he was developing to treat an Ebola-like viral infection called Marburg, his first question was, “Who is this?”After learning a researcher studying the virus had been accidentally exposed...
You are here
MAPP BIOPHARMACEUTICAL, INC.
Company Information
Information
UEI: M9V9QTHR1H28
# of Employees: 70
Ownership Information
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Marburg Virus Prophylactic Medical Countermeasure
Amount: $999,034.00There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents ...
STTRPhase II2020Department of Defense Office for Chemical and Biological Defense -
Development of highly potent human monoclonal for RSV immuno-prophylaxis
Amount: $2,747,713.00PROJECT SUMMARY Respiratory syncytial virus (RSV) is a leading cause of infant hospitalizations in the U.S., and the disease burden among the elderly is similar to non-pandemic influenza A. Traditiona ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Development of highly potent human monoclonals for RSV immunoprophylaxis
Amount: $600,000.00PROJECT SUMMARY Respiratory syncytial virusRSVis a leading cause of infant hospitalizations in the U Sand the disease burden among the elderly is similar to non pandemic influenza ATraditional strateg ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Post-exposure immunotherapy for ricin exposure
Amount: $298,015.00PROJECT SUMMARYRicin is a category B toxin due to its ease of acquisitiondisseminationand the high potential for morbidity and mortality after exposureRicin is naturally produced by the castor bean pl ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Marburg Virus Prophylactic Medical Countermeasure
Amount: $149,998.70There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents ...
STTRPhase I2018Department of Defense Office for Chemical and Biological Defense -
Direct sequencing of serum antibodies after infection
Amount: $255,046.00Project Summary Monoclonal antibodies mAbs are a well validated drug platform with exquisite specificity diversity and potency They offer the lowest risk class of drug for development through lice ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life
Amount: $999,927.75Ricin is a category B toxin due to its ease of acquisition, dissemination, and the high potential for morbidity and mortality after exposure. Ricin in semi-purified or purified form is extremely toxic ...
SBIRPhase II2017Department of Defense Army -
MR191_An Immunoprotectantfor Marburg Virus
Amount: $3,000,000.00PROJECT SUMMARY Mapp BiopharmaceuticalIncMappis developing antibody based therapeutics to treat a number of infectious agentsincluding some of the most dangerous known to manthe filovirusesMarburg vir ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Direct Sequencing of Antibodies of the Influenza Immune Response
Amount: $225,000.00Abstract The annual epidemics of influenza result in a substantial number of hospitalizations with an estimated to million cases of severe disease and to deaths globally During t ...
SBIRPhase I2017Department of Health and Human Services Centers for Disease Control and Prevention -
Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis
Amount: $240,221.00Summarty Abstract Vectored immunoprophylaxis or antibody gene transfer for infectious disease is a promising new strategy to provide protection against high risk infectious agents supplementing v ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health
